List of Excipients in Branded Drug PAIN RELIEF IBUPROFEN

Generic Drugs Containing PAIN RELIEF IBUPROFEN

Company	Ingredient	NDC	Excipient
Rite Aid Corporation	ibuprofen	11822-0292	ANHYDROUS LACTOSE
Rite Aid Corporation	ibuprofen	11822-0292	CARNAUBA WAX
Rite Aid Corporation	ibuprofen	11822-0292	CELLULOSE, MICROCRYSTALLINE
Rite Aid Corporation	ibuprofen	11822-0292	FERRIC OXIDE RED
Rite Aid Corporation	ibuprofen	11822-0292	HYPROMELLOSE

What are the Most Frequently-Used Excipients in PAIN RELIEF IBUPROFEN?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
2	CARNAUBA WAX
2	CELLULOSE, MICROCRYSTALLINE
1	FD&C YELLOW NO. 6 ALUMINUM LAKE
1	FERRIC OXIDE RED

Ibuprofen Excipient Strategy and Commercial Opportunities in OTC Pain Relief

Last updated: July 31, 2026

Ibuprofen is a mature, low-cost nonsteroidal anti-inflammatory drug (NSAID) with limited active-ingredient patent protection and intense generic competition. Commercial differentiation depends on formulation performance, dosage form, excipient selection, packaging, dosing convenience, pediatric acceptability, and regulatory positioning rather than on new chemical-entity exclusivity.

The strongest opportunities are liquid-filled softgels, rapid-release tablets, low-sugar pediatric liquids, chewable products, combination products permitted under the applicable regulatory pathway, and differentiated products for consumers who prioritize swallowing ease, onset perception, or gastrointestinal tolerability. Any commercial claim must remain consistent with FDA labeling and the applicable OTC monograph or approved application.

What is the regulatory status of pain relief ibuprofen in the United States?

Ibuprofen is an FDA-recognized OTC analgesic and antipyretic active ingredient. The FDA OTC monograph for internal analgesic, antipyretic, and antirheumatic products establishes permitted active ingredients, indications, doses, warnings, and labeling conditions for covered products.[1]

Typical adult OTC ibuprofen labeling provides:

Attribute	Typical OTC position
Active ingredient	Ibuprofen
Drug class	NSAID
Common strength	200 mg per unit
Indications	Temporary relief of minor aches and pains; reduction of fever
Common dosage form	Tablet, caplet, softgel, suspension
Adult and age 12+ dose	200 mg every 4 to 6 hours as needed
Maximum OTC daily dose	1,200 mg unless directed by a physician
Pediatric use	Weight- and age-based dosing under product labeling
Key warnings	Stomach bleeding, cardiovascular risk, allergic reactions, pregnancy-related restrictions, interactions with other NSAIDs and certain medicines

Prescription ibuprofen products may fall under approved new drug applications, while many OTC products are marketed under the monograph system. Products relying on an approved application may have different Orange Book treatment from products marketed solely under the OTC monograph.

What excipients are used in ibuprofen tablets, capsules, softgels, and liquids?

Excipient selection depends on the dosage form, release target, manufacturing process, sensory profile, and stability requirements.

Dosage form	Common excipient functions	Commercial objective
Immediate-release tablet	Diluent, binder, disintegrant, lubricant, glidant, coating polymer	Low cost, rapid disintegration, robust compression
Film-coated caplet	Film former, plasticizer, pigment, opacifier, anti-tacking agent	Swallowability, appearance, brand differentiation
Liquid-filled softgel	Solubilizer, cosolvent, surfactant, viscosity modifier, gelatin or alternative shell	Fast dispersion, smooth mouthfeel, swallowing ease
Oral suspension	Suspending agent, wetting agent, buffer, sweetener, flavor, preservative	Dose uniformity, sedimentation control, pediatric acceptance
Chewable tablet	Sweetener, flavor, binder, lubricant, disintegrant	Taste masking and convenient administration
Effervescent product	Acid, carbonate or bicarbonate, flavor, sweetener	Rapid dissolution and differentiated consumer experience
Liquid-filled capsule	Solvent system, surfactant, antioxidant, capsule shell	Consistent fill and rapid release

Ibuprofen has low water solubility. The formulation challenge is therefore not simply tablet disintegration. Developers must control wetting, dispersion, dissolution, content uniformity, and precipitation after exposure to gastrointestinal fluids.

How does ibuprofen solubility affect excipient strategy?

Ibuprofen is a weak acid with pH-dependent solubility. Its solubility generally improves as pH increases, but excessive alkalinity can affect taste, tolerability, capsule-shell compatibility, and product stability.

Immediate-release tablets

Conventional tablets usually use micronized or controlled-particle-size ibuprofen with a disintegrant system. Crospovidone, croscarmellose sodium, sodium starch glycolate, and related materials can improve water penetration and tablet breakup. The formulation must balance rapid disintegration against tablet hardness and friability.

Key development variables include:

• Ibuprofen particle-size distribution
• Granulation method
• Disintegrant concentration and location
• Lubrication time
• Compression force
• Tablet porosity
• Dissolution across relevant pH conditions
• Stability under heat and humidity

A low-cost direct-compression formulation may have the best manufacturing economics, but wet granulation can improve flow and content uniformity where the active has poor flow or high loading.

Liquid-filled softgels

Softgels can position ibuprofen as a faster-acting or easier-to-swallow product, but the commercial claim must be supported by appropriate dissolution, pharmacokinetic, or clinical evidence. A liquid fill may use a solvent or cosolvent system, surfactant, and viscosity modifier to improve dispersion.

The key risks are:

• Fill leakage or migration through the shell
• Gelatin cross-linking
• Precipitation during storage
• Shell brittleness or softening
• Interaction between the fill and capsule shell
• Oxidative degradation of excipients
• Higher cost than compressed tablets

Softgel products can command a premium if the consumer perceives meaningful benefits from swallowability, rapid dispersion, or unit-dose convenience.

Oral suspensions

Pediatric ibuprofen suspensions require more than an acceptable flavor. The formulation must maintain dose uniformity throughout the bottle, redisperse after storage, limit sedimentation, and provide an accurate dose with the supplied syringe or cup.

A typical suspension platform may include:

• Suspending polymer
• Wetting agent
• Buffer
• Sweetener
• Flavor
• Preservative, where needed
• Antifoam or processing aid
• Purified water

Sucrose-free formulations using sorbitol, glycerin, sucralose, or other sweetening systems can target parents seeking lower-sugar products. Preservative-free multidose systems may offer differentiation but require stronger microbiological control and packaging design.

What formulation patents protect ibuprofen products?

The basic ibuprofen molecule is off-patent. U.S. Patent No. 3,385,886, assigned to Boots Pure Drug Company, covered ibuprofen-related compounds and was issued in 1968.[2] Under the historical U.S. patent-term rules applicable to that patent, core protection expired decades ago.

Current commercial protection is more likely to arise from:

• Specific liquid or semisolid formulations
• Salt or solvate forms
• Particle-size or crystal-form controls
• Modified-release systems
• Combination products
• Pediatric delivery systems
• Manufacturing processes
• Device and package configurations
• Brand trademarks and trade dress

A formulation patent must be evaluated claim by claim. The presence of a patent family does not establish enforceability, commercial relevance, or freedom-to-operate risk. For OTC ibuprofen, excipient combinations that are conventional and predictable may face greater obviousness risk than technically difficult delivery systems supported by comparative data.

How many patents cover commercial ibuprofen products?

There is no single meaningful patent count for "ibuprofen" without defining the jurisdiction, product, dosage form, assignee, and claim scope. The relevant distinction is between:

1. Expired composition-of-matter protection.
2. Potentially active formulation or process patents.
3. Brand and trade-dress rights.
4. Patents covering combination products or delivery devices.

A commercial diligence review should search the USPTO, WIPO PATENTSCOPE, Google Patents, and relevant national registers by:

• Ibuprofen and chemical synonyms
• Product brand names
• Current and former manufacturers
• Formulation excipients
• Dosage form terms
• Inventor names
• Continuation and divisional applications
• Patent-term adjustment and terminal-disclaimer data

A patent family that claims a particular excipient ratio may be avoidable through a different formulation architecture. A process claim can create a manufacturing constraint even when the finished product can be designed around it.

When does ibuprofen lose exclusivity?

Ibuprofen lost core chemical exclusivity decades ago. Generic and private-label manufacturers can market conventional immediate-release ibuprofen products subject to FDA requirements.

The principal regulatory distinction is:

Product pathway	Exclusivity position
OTC monograph ibuprofen	No branded NCE exclusivity; compliance depends on monograph conditions
Approved branded ibuprofen NDA	Any application-specific exclusivity or listed patent rights depend on the individual NDA
Generic ibuprofen NDA/ANDA	Competes on a small-molecule active ingredient with mature supply and manufacturing standards
Novel ibuprofen formulation	May obtain limited patent value, but regulatory exclusivity depends on the approval pathway

OTC monograph reform under the Coronavirus Aid, Relief, and Economic Security Act changed the statutory framework for certain OTC products, but it did not restore composition-of-matter exclusivity to ibuprofen.[3]

What is the Orange Book status of ibuprofen products?

The FDA Orange Book identifies approved drug products and, where applicable, patent and exclusivity information for approved applications.[4] OTC monograph products do not automatically have the same Orange Book profile as prescription or NDA-based products.

For a specific branded ibuprofen product, the relevant review should confirm:

• Whether the product is marketed under an NDA
• Whether the NDA is active
• Whether patents are listed
• Whether any pediatric or other exclusivity period applies
• Whether an ANDA pathway is available
• Whether the product is marketed under the OTC monograph rather than an approved application

The Orange Book should be reviewed together with FDA Drugs@FDA, the OTC monograph, patent registers, and current labeling. A generic applicant’s risk profile depends on the specific reference product and regulatory route.

Are there Paragraph IV challenges for ibuprofen?

Paragraph IV litigation is generally associated with ANDA applicants challenging patents listed for an approved reference drug. Conventional OTC monograph ibuprofen products do not create the same patent-certification structure as a heavily protected prescription NDA.

For ibuprofen, Paragraph IV risk is more likely to arise in relation to:

• A branded NDA product with listed formulation patents
• A novel release profile
• A combination product
• A liquid-filled or softgel formulation
• A device-linked presentation
• A product with later-added patent listings

A generic applicant should distinguish between the absence of core ibuprofen patents and the possible presence of narrower product-specific patents. The latter may affect launch timing without changing the overall market’s competitive structure.

What generic entry risks exist for ibuprofen?

Generic entry risk is high for conventional 200 mg tablets, caplets, and standard suspensions. The active ingredient is widely available, the dosage forms are established, and consumers are familiar with private-label alternatives.

The main barriers are operational rather than molecular:

• Reliable API sourcing
• Control of particle size and polymorphic form
• Dissolution performance
• Taste masking
• Suspension stability
• Softgel-shell compatibility
• FDA-compliant labeling
• Child-resistant packaging
• Quality-system compliance
• Retailer qualification
• Supply continuity

A generic launch can fail commercially even when regulatory approval is straightforward. Retail buyers often prioritize delivered cost, fill rate, packaging efficiency, promotional support, and product reviews.

What commercial opportunities exist for ibuprofen excipient innovation?

Fast-dissolving and rapid-release products

A rapid-release platform can use particle engineering, wetting agents, superdisintegrants, porous carriers, or self-emulsifying systems. The strongest commercial position requires comparative dissolution data and, where claims extend beyond dissolution, suitable pharmacokinetic evidence.

Potential claims include:

• Rapid disintegration
• Rapid dissolution
• Easy swallowing
• Convenient dosing
• Reduced tablet size

"Faster pain relief" is a higher-risk claim than "rapid dissolution" because it implies a clinical or pharmacokinetic benefit.

Low-sugar pediatric suspensions

Pediatric liquids remain a strong excipient-led opportunity. Commercial differentiation can come from:

• Sucrose-free formulation
• Improved flavor system
• Lower viscosity
• Accurate oral syringe dosing
• Reduced foaming
• Easier redispersion
• Single-dose sachets
• Preservative-reduced or preservative-free packaging

The product must preserve dose uniformity and microbiological quality. Taste masking cannot compromise dissolution or create excessive sweetness that increases accidental-ingestion concerns.

Chewable and orally disintegrating products

Chewables can target children and adults who avoid tablets. The core technical problem is taste. Ibuprofen’s bitterness and acidic character may require polymeric taste-masking systems, coated particles, ion-exchange approaches, or multilayer granules.

Commercial risks include:

• High tablet mass at a 200 mg dose
• Chalky or gritty mouthfeel
• Delayed release from excessive coating
• Dental and sweetener considerations
• Dose confusion in pediatric use

Softgels and liquid-filled capsules

Softgels provide a clear premiumization route. They can differentiate the product through smooth swallowing, unit-dose packaging, and a distinct tactile experience. The platform usually carries higher manufacturing and packaging costs, so it is best suited to branded, store-brand premium, or travel-oriented products.

Effervescent and soluble formats

Effervescent ibuprofen can offer rapid preparation and a novel consumer experience. The development burden includes moisture protection, acid-base compatibility, flavor, sodium content, package barrier performance, and dosage accuracy.

A high-barrier tube or foil pouch may be required. Packaging can become a material part of the product’s cost structure and patent strategy.

Combination analgesics

Ibuprofen may be combined with acetaminophen or other permitted actives, subject to the applicable FDA regulatory pathway and labeling requirements. Combination products can increase consumer convenience but also increase:

• Dose-complexity risk
• Labeling burden
• Interaction concerns
• Safety-review requirements
• Patent and regulatory diligence
• Consumer confusion about duplicate NSAID exposure

Combination products should be evaluated as new commercial and regulatory assets rather than simple extensions of single-ingredient ibuprofen.

How strong is the patent estate for ibuprofen excipient technology?

The patent estate for the active ingredient is weak because core protection is expired. The estate for a specific delivery system can be stronger when it includes:

• Narrow but technically defensible formulation claims
• Comparative dissolution or pharmacokinetic data
• Stable commercial-scale manufacturing
• Difficult-to-reproduce particle engineering
• A meaningful consumer benefit
• Multiple claim categories covering composition, process, and use

Patent strength is lower when the claims rely on routine excipients at conventional concentrations without unexpected results. Freedom-to-operate analysis should examine active patents, pending applications, terminal disclaimers, continuations, prosecution history, and foreign counterparts.

Trade secrets may be more valuable than patents for flavor systems, particle engineering, granulation parameters, and manufacturing controls. Trade-secret protection does not prevent independent development, reverse engineering, or employee mobility.

Which companies compete in the ibuprofen market?

The market includes branded manufacturers, private-label retailers, generic pharmaceutical companies, contract manufacturers, and API suppliers.

Competitive group	Typical advantage
Branded OTC manufacturers	Consumer recognition, advertising, premium formats
Large generic companies	Scale, low cost, regulatory infrastructure
Retail private labels	Shelf access, price, retailer promotion
Contract manufacturers	Flexible production and dosage-form expertise
Softgel specialists	Encapsulation capability and premium presentations
Pediatric-focused companies	Flavor, dosing devices, parent-oriented packaging
API producers	Cost control and supply-chain leverage

The competitive advantage often lies outside the active ingredient. A supplier with dependable softgel capacity, pediatric flavor expertise, or high-throughput tablet coating may capture more value than a company with no differentiated formulation but lower API cost.

What manufacturing and intellectual-property barriers affect ibuprofen?

Manufacturing barriers vary by dosage form.

Tablets

The primary risks are flow, sticking, capping, lubrication, hardness, and dissolution variability. High ibuprofen loading can constrain excipient space and increase tablet size.

Softgels

The critical barriers are fill formulation, shell compatibility, seam integrity, oxygen and moisture control, and high capital requirements.

Suspensions

The main risks are sedimentation, caking, microbial control, flavor stability, and dose uniformity throughout the bottle.

Effervescent products

Moisture sensitivity is the dominant manufacturing and packaging issue. A product can have acceptable laboratory stability but fail in commercial distribution if the package barrier is inadequate.

A scalable formulation should be tested under accelerated and long-term stability conditions, including in the final commercial container-closure system. Process validation should address raw-material variability, especially for polymers, surfactants, flavors, and particle-size-sensitive ingredients.

What licensing deals are available for ibuprofen excipient technology?

Ibuprofen itself is broadly available from established API suppliers and does not generally require a license to practice the expired core chemistry. Licensing opportunities are more likely to involve:

• Proprietary solubilization systems
• Taste-masking technology
• Spray-dried or coated particles
• Softgel fill systems
• Novel suspension platforms
• Drug-delivery devices
• Proprietary packaging
• Combination-product brands

A licensing transaction should separate rights to the formulation, manufacturing process, trademarks, regulatory dossier, and supply agreement. The commercial value of an excipient platform depends on whether the licensor has demonstrated scale-up, stability, regulatory acceptability, and freedom to operate.

What revenue exposure does ibuprofen create for manufacturers?

Conventional ibuprofen is a high-volume but low-margin product. Revenue is exposed to:

• Retail price competition
• Private-label substitution
• Promotional discounting
• API price changes
• Retailer concentration
• Product recalls
• Supply disruptions
• Demand volatility during cold and flu seasons
• Consumer migration between tablets, softgels, liquids, and combination products

Premium formats can improve gross margin, but the premium must exceed the cost of specialized excipients, packaging, quality testing, and manufacturing losses. Pediatric products and softgels usually provide greater differentiation than standard tablets, while standard 200 mg tablets remain the most price-sensitive segment.

What generic launch scenarios are most likely for ibuprofen?

Launch scenario	Market impact	Commercial assessment
Standard 200 mg tablet	Rapid price competition	Lowest barrier, weakest differentiation
Film-coated caplet	Moderate substitution	Branding and packaging can support modest premium
Liquid-filled softgel	Premium competition	Higher technical and manufacturing barrier
Pediatric suspension	Brand and flavor competition	Strong opportunity for dosing and taste differentiation
Chewable tablet	Targeted pediatric and adult segment	Requires effective taste masking
Effervescent product	New usage occasion	Packaging and moisture control are critical
Combination product	Higher perceived convenience	Greater regulatory and safety complexity

Key Takeaways

• Ibuprofen’s core composition-of-matter protection is expired.
• Conventional tablets and suspensions face high generic and private-label competition.
• Excipient strategy is the main route to product differentiation.
• The strongest platforms are rapid-release, softgel, pediatric low-sugar, chewable, and effervescent formats.
• Ibuprofen’s low solubility makes wetting, dispersion, dissolution, and precipitation control central development issues.
• Formulation patents can create value, but routine excipient combinations may have limited enforceability.
• OTC monograph status reduces the relevance of conventional NCE exclusivity.
• Orange Book and Paragraph IV analysis depends on the specific NDA or reference product.
• Manufacturing know-how, flavor systems, particle engineering, and packaging may be more commercially important than the expired ibuprofen molecule patent.
• Premium pricing must compensate for specialized excipients, validation, packaging, and supply-chain costs.

FAQs About Ibuprofen Excipient Strategy and Commercialization

Can ibuprofen be formulated without lactose?

Yes. Lactose-free tablets can use microcrystalline cellulose, mannitol, calcium phosphate, starches, or other suitable diluents, subject to manufacturability, stability, dissolution, and labeling requirements.

Which excipient improves ibuprofen dissolution most effectively?

No single excipient is universally optimal. Performance depends on particle size, disintegrant system, wetting agent, granulation process, compression force, and dissolution medium. Comparative formulation testing is required.

Is micronized ibuprofen patentable?

Particle-size claims may be patentable if they meet novelty and non-obviousness standards and produce a defensible technical effect. Generic micronization alone may not provide durable patent protection.

Does ibuprofen have biosimilar competition?

No. Ibuprofen is a chemically synthesized small molecule, so competition is evaluated through generic-drug and formulation pathways rather than biosimilar pathways.

What is the most attractive ibuprofen product segment?

Premium liquid-filled softgels and differentiated pediatric suspensions generally offer stronger commercial positioning than standard tablets. Their value depends on consumer acceptance, manufacturing scale, regulatory compliance, and defensible performance claims.

References

1. U.S. Food and Drug Administration. (2022). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. Electronic Code of Federal Regulations.
2. Boots Pure Drug Company Limited. (1968). U.S. Patent No. 3,385,886: Anti-inflammatory agents. United States Patent and Trademark Office.
3. U.S. Congress. (2020). Coronavirus Aid, Relief, and Economic Security Act, Pub. L. No. 116-136, § 3851.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.